Podar K, Leleu X. Relapsed/refractory multiple myeloma in 2020/2021 and beyond. Cancers. 2021;13(20).

Sunder-Plassmann V, Aksoy O, Lind J, Pecherstorfer M, Vallet S, Podar K. On the continuous (R)evolution of antibody-based and CAR T cell therapies in multiple myeloma: an early 2022 glance into the future. Expert Opin Pharmacother. 2022;23(12):1425–44.

Article  CAS  PubMed  Google Scholar 

Kumar SK, Callander NS, Adekola K, Anderson LD Jr., Baljevic M, Baz R, et al. Multiple myeloma, version 2.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023;21(12):1281–301.

Article  PubMed  Google Scholar 

Easson EC, Russell MH. Cure of Hodgkin’s disease. Br Med J. 1963;1(5347):1704–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kwan A, Chadwick N, Hancock B. Improving survival of patients with Hodgkin lymphoma over 4 decades: experience of the British national lymphoma investigation (BNLI) with 6834 patients. Clin Lymphoma Myeloma Leuk. 2017;17(2):108–19.

Article  PubMed  Google Scholar 

Mohty M, Avet-Loiseau H, Harousseau JL. Requirements for operational cure in multiple myeloma. Blood. 2021;138(16):1406–11.

Article  CAS  PubMed  Google Scholar 

Mohty M, Avet-Loiseau H, Malard F, Harousseau JL. Potential future direction of measurable residual disease evaluation in multiple myeloma. Blood. 2023;142(18):1509–17.

Article  CAS  PubMed  Google Scholar 

Mateos MV, Nooka AK, Larson SM. Moving toward a cure for myeloma. Am Soc Clin Oncol Educ Book. 2022;42:1–12.

PubMed  Google Scholar 

Derman BA, Jakubowiak AJ. Moving toward a cure in multiple myeloma: eradication of measurable residual disease. Adv Oncol. 2022;2:159–69.

Article  Google Scholar 

Gahrton G, Tura S, Ljungman P, Belanger C, Brandt L, Cavo M, et al. Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med. 1991;325(18):1267–73.

Article  CAS  PubMed  Google Scholar 

Gahrton G, Tura S, Ljungman P, Blade J, Cavo M, De Laurenzi A, et al. An update of prognostic factors for allogeneic bone marrow transplantation in multiple myeloma using matched sibling donors. European Group for Blood and Marrow Transplantation. Stem Cells. 1995;13(Suppl 2):122–5.

PubMed  Google Scholar 

Greil C, Engelhardt M, Finke J, Wasch R. Allogeneic stem cell transplantation in multiple myeloma. Cancers. 2021;14(1).

Barlogie B. Toward a cure for multiple myeloma? N Engl J Med. 1991;325(18):1304–6.

Article  CAS  PubMed  Google Scholar 

Fassas A, Shaughnessy J, Barlogie B. Cure of myeloma: hype or reality? Bone Marrow Transplant. 2005;35(3):215–24.

Article  CAS  PubMed  Google Scholar 

Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J. Curing myeloma at last: defining criteria and providing the evidence. Blood. 2014;124(20):3043–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bahlis NJ. Darwinian evolution and tiding clones in multiple myeloma. Blood. 2012;120(5):927–8.

Article  CAS  PubMed  Google Scholar 

Rasche L, Chavan SS, Stephens OW, Patel PH, Tytarenko R, Ashby C, et al. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat Commun. 2017;8(1):268.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rasche L, Schinke C, Maura F, Bauer MA, Ashby C, Deshpande S, et al. The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states. Nat Commun. 2022;13(1):4517.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Merz M, Hu Q, Merz AMA, Wang J, Hutson N, Rondeau C, et al. Spatiotemporal assessment of immunogenomic heterogeneity in multiple myeloma. Blood Adv. 2023;7(5):718–33.

Article  CAS  PubMed  Google Scholar 

Al Hadidi S, Ababneh O, Schinke C, Thanendrarajan S, Bailey C, Smith RT, et al. Long term follow up of total therapy IV: a phase III clinical trial for standard risk multiple myeloma. Blood Adv . 2025 Feb 25;9(4):950–953.

Article  PubMed  Google Scholar 

Powles R, Mehta J, Kulkarni S, Treleaven J, Millar B, Marsden J, et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet. 2000;355(9211):1231–7.

Article  CAS  PubMed  Google Scholar 

Puertas B, Gonzalez-Calle V, Sobejano-Fuertes E, Escalante F, Queizan JA, Barez A, et al. Novel agents as main drivers for continued improvement in survival in multiple myeloma. Cancers. 2023;15(5).

Rajkumar SV. Treatment of myeloma: cure vs control. Mayo Clin Proc. 2008;83(10):1142–5.

Article  PubMed  Google Scholar 

Rajkumar SV, Gahrton G, Bergsagel PL. Approach to the treatment of multiple myeloma: a clash of philosophies. Blood. 2011;118(12):3205–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Landgren O, Prior TJ, Masterson T, Heuck C, Bueno OF, Dash AB, et al. EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma. Blood. 2024;144(4):359–67.

Article  CAS  PubMed  Google Scholar 

Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4(23):5988–99.

Article  PubMed  PubMed Central  Google Scholar 

Munshi NC, Avet-Loiseau H, Rawstron AC, Owen RG, Child JA, Thakurta A, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol. 2017;3(1):28–35.

Article  PubMed  PubMed Central  Google Scholar 

Perrot A, Lauwers-Cances V, Corre J, Robillard N, Hulin C, Chretien ML, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018;132(23):2456–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bahlis NJ, Dimopoulos MA, White DJ, Benboubker L, Cook G, Leiba M, et al. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia. 2020;34(7):1875–84.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(14):1319–31.

Article  CAS  PubMed  Google Scholar 

Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754–66.

Article  CAS  PubMed  Google Scholar 

Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;390(4):301–13.

Article  CAS  PubMed  Google Scholar 

Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e46.

Article  PubMed  Google Scholar 

Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, Garcia-Sanchez O, Bottcher S, et al. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31(10):2094–103.

Article